NCT06022406View on ClinicalTrials.gov

Fecal Microbiota Translantation (FMT) to Reduce Inflammation in PLWH: The Gutsy Pilot Study

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

August 13, 2025

Study Completion Date

August 13, 2025

Conditions
HIV-1-infection
Interventions
BIOLOGICAL

FMT capsules

Formulation: 80-100g of healthy donor stool processed, frozen and encapsulated in gelatin capsules (modified Kao et al, 2017).

BIOLOGICAL

Placebo capsules

Formulation: microcrystalline cellulose, for equivalence in weight and color, will be encapsulated in gelatin capsules. Each capsule will be filled with approximatively 5.5g of microcrystalline cellulose, and encapsulated in size 0 and size 00 capsules.

Trial Locations (1)

H4A 3J1

Chronic Viral Illness Service, Montreal

All Listed Sponsors
collaborator

St. Joseph's Health Care London

OTHER

lead

Jean-Pierre Routy

OTHER

NCT06022406 - Fecal Microbiota Translantation (FMT) to Reduce Inflammation in PLWH: The Gutsy Pilot Study | Biotech Hunter | Biotech Hunter